4.7 Article

MicroRNA-199a-5p Is Associated With Hypoxia-Inducible Factor-1α Expression in Lungs From Patients With COPD

期刊

CHEST
卷 142, 期 3, 页码 663-672

出版社

AMER COLL CHEST PHYSICIANS
DOI: 10.1378/chest.11-2746

关键词

-

资金

  1. National Institutes of Health [N01-HR-46160-3]
  2. Victoria Johnson Center for Lung Research of the Virginia Commonwealth University

向作者/读者索取更多资源

Background: MicroRNAs (miRNAs) are small noncoding RNAs that silence target gene expression posttranscriptionally, and their impact on gene expression has been reported in various diseases. It has been reported that the expression of the hypoxia-inducible factor-1 alpha (HIF-1 alpha) is reduced and that of p53 is increased in lungs from patients with COPD. However, the role of miRNAs associated with these genes in lungs from patients with COPD is unknown. Methods: Lung tissue samples from 55 patients were included in this study. Total RNA, miRNA, and protein were extracted from lung tissues and used for reverse transcriptase polymerase chain reaction and Western blot analysis. Cell culture experiments were performed using cultured human pulmonary microvascular endothelial cells (HPMVECs). Results: miR-34a and miR-199a-5p expressions were increased, and the phosphorylation of AKT was decreased in the lung tissue samples of patients with COPD. The miA-199a-5p expression was correlated with HIF-1 alpha protein expression in the lungs of patients with COPD. Transfection of HPMVECs with the miR-199a-5p precursor gene decreased HIF-1 alpha protein expression, and transfection with the miR-34a precursor gene increased miR-199a-5p expression. Conclusions: These data suggest that miR-34a and miR-199a-5p contribute to the pathogenesis of COPD, and these miRNAs may also affect the HIF-1 alpha-dependent lung structure maintenance program. CHEST 2012; 142 (3):663-672

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Article Cardiac & Cardiovascular Systems

Bayesian Inference Associates Rare KDR Variants With Specific Phenotypes in Pulmonary Arterial Hypertension

Emilia M. Swietlik, Daniel Greene, Na Zhu, Karyn Megy, Marcella Cogliano, Smitha Rajaram, Divya Pandya, Tobias Tilly, Katie A. Lutz, Carrie C. L. Welch, Michael W. Pauciulo, Laura Southgate, Jennifer M. Martin, Carmen M. Treacy, Christopher J. Penkett, Jonathan C. Stephens, Harm J. Bogaard, Colin Church, Gerry Coghlan, Anna W. Coleman, Robin Condliffe, Christina A. Eichstaedt, Melanie Eyries, Henning Gall, Stefano Ghio, Barbara Girerd, Ekkehard Grunig, Simon Holden, Luke Howard, Marc Humbert, David G. Kiely, Gabor Kovacs, Jim Lordan, Rajiv D. Machado, Robert V. Mackenzie Ross, Colm McCabe, Shahin Moledina, David Montani, Horst Olschewski, Joanna Pepke-Zaba, Laura Price, Christopher J. Rhodes, Werner Seeger, Florent Soubrier, Jay Suntharalingam, Mark R. Toshner, Anton Vonk Noordegraaf, John Wharton, James M. Wild, Stephen John Wort, Allan Lawrie, Martin R. Wilkins, Richard C. Trembath, Yufeng Shen, Wendy K. Chung, Andrew J. Swift, William C. Nichols, Nicholas W. Morrell, Stefan Graf

Summary: Approximately 25% of PAH patients have rare mutations in disease-causing genes. By integrating deep phenotyping with whole-genome sequencing, we identified a novel candidate gene, KDR, associated with distinct phenotypes in PAH. This finding highlights the importance of the vascular endothelium in the pathobiology of PAH.

CIRCULATION-GENOMIC AND PRECISION MEDICINE (2021)

Article Peripheral Vascular Disease

Inhibition of the prolyl isomerase Pin1 improves endothelial function and attenuates vascular remodelling in pulmonary hypertension by inhibiting TGF-β signalling

Kondababu Kurakula, Quint A. J. Hagdorn, Diederik E. van der Feen, Anton Vonk Noordegraaf, Peter ten Dijke, Rudolf A. de Boer, Harm Jan Bogaard, Marie Jose Goumans, Rolf M. F. Berger

Summary: Pulmonary arterial hypertension (PAH) is a devastating disease characterized by obstructive pulmonary vascular remodeling. Targeting Pin1 could potentially reverse the phenotype of PAH through modulation of TGF-beta/BMP signaling pathways, providing a novel therapeutic option for PAH treatment.

ANGIOGENESIS (2022)

Article Respiratory System

Evolution of CT findings after anticoagulant treatment for acute pulmonary embolism in patients with and without an ultimate diagnosis of chronic thromboembolic pulmonary hypertension

Natalia J. Braams, Gudula J. A. M. Boon, Frances S. de Man, Josien van Es, Paul L. den Exter, Lucia J. M. Kroft, Ludo F. M. Beenen, Menno Huisman, Esther J. Nossent, Anco Boonstra, Anton Vonk Noordegraaf, Dieuwertje Ruigrok, Frederikus A. Klok, Harm Jan Bogaard, Lilian J. Meijboom

Summary: In patients with acute PE, central thrombi resolved after anticoagulant treatment, while mural thrombi and total thrombotic occlusions either resolved or evolved into webs or tapered pulmonary arteries. Patients with a diagnosis of CTEPH had webs and tapered pulmonary arteries on the baseline scan, which persisted after follow-up. Webs and tapered pulmonary arteries at the time of PE diagnosis strongly indicate a state of chronic PE and should raise awareness for possible CTEPH.

EUROPEAN RESPIRATORY JOURNAL (2021)

Article Critical Care Medicine

Epigenetic Modification of the von Willebrand Factor Promoter Drives Platelet Aggregation on the Pulmonary Endothelium in Chronic Thromboembolic Pulmonary Hypertension

Xue D. Manz, Robert Szulcek, Xiaoke Pan, Petr Symersky, Chris Dickhoff, Jisca Majolee, Veerle Kremer, Elisabetta Michielon, Ekaterina S. Jordanova, Teodora Radonic, Irene Bijnsdorp, Sander R. Piersma, Thang Pham, Connie R. Jimenez, Anton Vonk Noordegraaf, Frances S. de Man, Reinier A. Boon, Jan Voorberg, Peter L. Hordijk, Jurjan Aman, Harm Jan Bogaard

Summary: This study identifies the role of von Willebrand factor (vWF) in chronic thromboembolic pulmonary hypertension (CTEPH). Increased vWF levels in plasma and pulmonary endothelium of CTEPH patients contribute to elevated platelet adhesion to CTEPH endothelium. The increased expression of nuclear factor (NF)-kappa B2 and epigenetic modifications of the vWF promoter play a critical role in driving vWF transcription and promoting a prothrombotic phenotype in CTEPH-pulmonary artery endothelial cells.

AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2022)

Article Cardiac & Cardiovascular Systems

Right Ventricular and Right Atrial Function Are Less Compromised in Pulmonary Hypertension Secondary to Heart Failure With Preserved Ejection Fraction: A Comparison With Pulmonary Arterial Hypertension With Similar Pressure Overload

Jessie van Wezenbeek, Azar Kianzad, Arno van de Bovenkamp, Jeroen Wessels, Sophia A. Mouratoglou, Natalia J. Braams, Samara M. A. Jansen, Eva Meulblok, Lilian J. Meijboom, J. Tim Marcus, Anton Vonk Noordegraaf, Marie Jose Goumans, Harm Jan Bogaard, M. Louis Handoko, Frances S. de Man

Summary: This study compared cardiac function in HFpEF, HFpEF-PH, and PAH patients and found that despite similar pressure overload, RV/RA function was less compromised in HFpEF-PH compared to PAH. The increased RA pressure and stiffness in HFpEF-PH were explained by left atrial/RA interaction.

CIRCULATION-HEART FAILURE (2022)

Article Cardiac & Cardiovascular Systems

Interplay of sex hormones and long-term right ventricular adaptation in a Dutch PAH-cohort

Jessie van Wezenbeek, Joanne A. Groeneveldt, Aida Llucia-Valldeperas, Cathelijne E. van Der Bruggen, Samara M. A. Jansen, A. Josien Smits, Rowan Smal, Joost W. van Leeuwen, Cris dos Remedios, Anne Keogh, Marc Humbert, Peter Dorfmuller, Olaf Mercier, Christophe Guignabert, Hans W. M. Niessen, M. Louis Handoko, J. Tim Marcus, Lilian J. Meijboom, Frank P. T. Oosterveer, Berend E. Westerhof, Annemieke C. Heijboer, Harm Jan Bogaard, Anton Vonk Noordegraaf, Marie Jose Goumans, Frances S. de Man

Summary: This study investigated the association between altered sex hormone expression and long-term right ventricular adaptation and progression of right heart failure in patients with pulmonary arterial hypertension across a wide range of ages.

JOURNAL OF HEART AND LUNG TRANSPLANTATION (2022)

Article Medicine, Research & Experimental

The INVENT COVID trial: a structured protocol for a randomized controlled trial investigating the efficacy and safety of intravenous imatinib mesylate (Impentri®) in subjects with acute respiratory distress syndrome induced by COVID-19

Leila Atmowihardjo, Job R. Schippers, Imke H. Bartelink, Pierre M. Bet, Nienke van Rein, Keith Purdy, David Cavalla, Valerie Comberiati, Andrew McElroy, Sue D. Snape, Harm Jan Bogaard, Leo Heunks, Nicole Juffermans, Marcus Schultz, Pieter R. Tuinman, Lieuwe D. J. Bos, Jurjan Aman

Summary: This study aims to investigate the efficacy and safety of IV imatinib in mechanically ventilated subjects with COVID-19-related ARDS. By reducing pulmonary edema, it may contribute to improving respiratory function and speeding up recovery.

TRIALS (2022)

Article Multidisciplinary Sciences

Metabolic profile in endothelial cells of chronic thromboembolic pulmonary hypertension and pulmonary arterial hypertension

V. F. E. D. Smolders, C. Rodriguez, I Blanco, R. Szulcek, Wim Timens, L. Piccari, Y. Roger, X. Hu, Constanza Moren, C. Bonjoch, L. Sebastian, M. Castella, J. Osorio, V. Peinado, Harm Jan Bogaard, P. H. A. Quax, M. Cascante, J. A. Barbera, O. Tura-Ceide

Summary: This study compares the metabolic characteristics of endothelial cells from patients with chronic thromboembolic pulmonary hypertension (CTEPH) and pulmonary arterial hypertension (PAH), and finds differences between them, suggesting different disease pathology and treatment mechanisms.

SCIENTIFIC REPORTS (2022)

Article Cardiac & Cardiovascular Systems

The Value of Passive Leg Raise During Right Heart Catheterization in Diagnosing Heart Failure With Preserved Ejection Fraction

Arno A. van de Bovenkamp, Niels Wijkstra, Frank P. T. Oosterveer, Anton Vonk Noordegraaf, Harm Jan Bogaard, Albert C. van Rossum, Frances S. de Man, Barry A. Borlaug, M. Louis Handoko

Summary: PCWPPLR during a passive leg raise can be a simple and powerful tool to diagnose or rule out occult-HFpEF, especially for patients with normal left ventricular filling pressures at rest.

CIRCULATION-HEART FAILURE (2022)

Article Cardiac & Cardiovascular Systems

Idiopathic pulmonary arterial hypertension patients with a high H2FPEF-score: Insights from the Amsterdam UMC PAH-cohort

Azar Kianzad, Jessie van Wezenbeek, Lucas R. Celant, Frank P. T. Oosterveer, Anton Vonk Noordegraaf, Lilian J. Meijboom, Frances S. de Man, Harm Jan Bogaard, M. Louis Handoko

Summary: The aim of this study was to determine whether the H2FPEF score identifies a subgroup of iPAH patients with a blunted response to PAH-targeted treatment. The results showed that patients with a high H2FPEF score had differences in age, gender, obesity, and comorbidities, and were associated with worse survival and functional capacity. However, the H2FPEF score did not predict the hemodynamic and functional responses to PAH treatment.

JOURNAL OF HEART AND LUNG TRANSPLANTATION (2022)

Article Critical Care Medicine

First Genotype-Phenotype Study in TBX4 Syndrome Gain-of-Function Mutations Causative for Lung Disease

Matina Prapa, Mauro Lago-Docampo, Emilia M. Swietlik, David Montani, Melanie Eyries, Marc Humbert, Carrie L. Welch, Wendy K. Chung, Rolf M. F. Berger, Harm Jan Bogaard, Olivier Danhaive, Pilar Escribano-Subias, Henning Gall, Barbara Girerd, Ignacio Hernandez-Gonzalez, Simon Holden, David Hunt, Samara M. A. Jansen, Wilhelmina Kerstjens-Frederikse, David G. Kiely, Pablo Lapunzina, John McDermott, Shahin Moledina, Joanna Pepke-Zaba, Gary J. Polwarth, Gwen Schotte, Jair Tenorio-Castano, A. A. Roger Thompson, John Wharton, Stephen J. Wort, Karyn Megy, Rutendo Mapeta, Carmen M. Treacy, Jennifer M. Martin, Wei Li, Andrew J. Swift, Paul D. Upton, Nicholas W. Morrell, Stefan Graf, Diana Valverde

Summary: This study analyzed TBX4-associated pulmonary arterial hypertension and found that TBX4 variants can cause both loss-of-function and gain-of-function effects. The differential impact of pathogenic mutations located in critical protein domains may explain the pleiotropic effects of TBX4 in lung disease.

AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2022)

Article Respiratory System

Immunomodulation and endothelial barrier protection mediate the association between oral imatinib and mortality in hospitalised COVID-19 patients

Justin de Brabander, Erik Duijvelaar, Job R. Schippers, Patrick J. Smeele, Hessel Peters-Sengers, Jan Willem Duitman, Jurjan Aman, Harm Jan Bogaard, Tom van der Poll, Lieuwe D. J. Bos

Summary: The effect of imatinib on mortality in hospitalised COVID-19 patients is mediated through modulation of innate immune responses and reversal of endothelial dysfunction, and possibly moderated by biological subphenotypes.

EUROPEAN RESPIRATORY JOURNAL (2022)

Review Hematology

Regulation of VWF (Von Willebrand Factor) in Inflammatory Thrombosis

Xue D. Manz, Harm Jan Bogaard, Jurjan Aman

Summary: Increasing evidence suggests that inflammation promotes thrombosis via VWF-mediated mechanisms, and aberrant regulation of VWF is linked to various cardiovascular diseases. Recent insights from clinical diseases provide evidence for direct molecular links between inflammation and thrombosis.

ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2022)

Article Oncology

Quality of life after patient-initiated vs physician-initiated response to symptom monitoring: the SYMPRO-Lung trial

Nicole E. Billingy, Vashti N. M. F. Tromp, Neil K. Aaronson, Rianne J. A. Hoek, Harm Jan Bogaard, Bregje D. Onwuteaka-Philipsen, Lonneke van de Poll-franse, Jacqueline G. Hugtenburg, Jose Belderbos, Annemarie Becker-Commissaris, Corina J. G. van den Hurk, Iris Walraven, N. C. van Walree, K. de Jaeger, S. Samii, W. Y. Lam-Wong, F. Koppe, J. A. Stigt, G. J. M. Herder, A. Welling, O. C. J. Schuurbiers-Siebers, J. M. Smit, A. J. van den Brekel, W. K. de Jong

Summary: This study compared the effect of reactive and active approaches in monitoring patient-reported outcome measures (PROMs) for lung cancer patients. The results showed that weekly PRO symptom monitoring significantly improved health-related quality of life (HRQOL) in these patients, with the reactive approach being more suitable for implementation.

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2023)

Article Health Care Sciences & Services

Precision Medicine for More Oxygen (P4O2)-Study Design and First Results of the Long COVID-19 Extension

Nadia Baalbaki, Jelle M. Blankestijn, Mahmoud I. Abdel-Aziz, Jan de Backer, Somayeh Bazdar, Ines Beekers, Rosanne J. H. C. G. Beijers, Joop P. van den Bergh, Lizan D. Bloemsma, Harm Jan Bogaard, Job J. M. H. van Bragt, Vera van den Brink, Jean Paul Charbonnier, Merel E. B. Cornelissen, Yennece Dagelet, Elin Haf Davies, Anne M. van der Does, George S. Downward, Cornelis M. van Drunen, Debbie Gach, J. J. Miranda Geelhoed, Jorrit Glastra, Kornel Golebski, Irene H. Heijink, Judith C. S. Holtjer, Sebastiaan Holverda, Laura Houweling, John J. L. Jacobs, Renee Jonker, Renate Kos, Ramon C. J. Langen, Ivo van der Lee, Asabi Leliveld, Firdaus A. A. Mohamed Hoesein, Anne H. Neerincx, Lieke Noij, Johan Olsson, Marianne van de Pol, Simon D. Pouwels, Emiel Rolink, Michael Rutgers, Havva Sahin, Daphne Schaminee, Annemie M. W. J. Schols, Lisanne Schuurman, Gitte Slingers, Olie Smeenk, Brigitte Sondermeijer, Paul J. Skipp, Marisca Tamarit, Inge Verkouter, Roel Vermeulen, Rianne de Vries, Els J. M. Weersink, Marco van de Werken, Yolanda de Wit-van Wijck, Stewart Young, Esther J. Nossent, Anke H. van der Zee

Summary: The P4O2 COVID-19 study aims to identify long COVID patients at risk for developing chronic lung disease and to find personalized therapeutic strategies. The study showed persistent symptoms and abnormalities in post-COVID patients, with the most commonly reported symptoms being respiratory and neurological symptoms.

JOURNAL OF PERSONALIZED MEDICINE (2023)

暂无数据